# NCT07475806 (NCT07475806)

> A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07475806
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Muscle-invasive Bladder Cancer
- Interventions: Enfortumab Vedotin; Pembrolizumab
- Enrollment: 240
- Primary outcome: Overall clinical complete response (cCR) rate after treatment with enfortumab vedotin in combination with pembrolizumab as assessed by investigator
- Primary outcome: Bladder-intact event-free survival (BI-EFS) rate in participants who achieve cRC after 9 cycles of treatment with enfortumab vedotin in combination with pembrolizumab as assessed by investigator

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 10
- Podcasts: 7
- YouTube: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct07475806

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07475806", "email": "<work email>"}; the inbox owner confirms by the emailed link.